ReST Therapeutics
ReST Therapeutics is a privately held clinical-stage biotech founded in 2020 and based in New Haven, Connecticut. It has 1–10 employees, is led by founder & CEO Gilles Rubinstenn, and has received two EIC Accelerator funding rounds (2021 and 2023).
- Company typePrivate
- Founded2020
- HeadquartersNew Haven, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
ReST Therapeutics firmographics
Firmographics- Name
- ReST Therapeutics
- Website
- https://rest-therapeutics.com
- Company type
- Private
- Founded year
- 2020
- Headcount range
- 1–10 employees
- Short description
- ReST Therapeutics is a privately held clinical-stage biotech founded in 2020 and based in New Haven, Connecticut. It has 1–10 employees, is led by founder & CEO Gilles Rubinstenn, and has received two EIC Accelerator funding rounds (2021 and 2023).
- Ownership category
- akta.pro rank
ReST Therapeutics industry classification
Industry- Product category
- Biotechnology
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro industry
- Neurology & CNS Specialty Pharmaceuticals
Keywords
Where ReST Therapeutics is headquartered
LocationHeadquarters
- HQ city
- New Haven
- HQ country
- United States
- HQ region
- North America
Markets served
ReST Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations
ReST Therapeutics product offering
Product offeringCore offering
ReST Therapeutics is described as a clinical-stage biotechnology company that has completed seed-stage funding. No specific therapeutic candidates, indications, modalities, or services are disclosed in the source material, and the company's website is currently an unavailable parked domain on Gandi.net, so detailed product/service specifics cannot be evidenced.
Differentiator
Problem solved
Functional benefit
Companies that use ReST Therapeutics
Customer profileIdeal customer profiles1 record
ReST Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
ReST Therapeutics competitors and assessment
Company assessmentDirect peers
- Avadel Pharmaceuticals: Specialty pharma developing therapeutics for sleep disorders, notably narcolepsy (FT218/Lumryz). Directly comparable to ReST as a CNS/sleep-focused clinical-stage biotech targeting the same therapeutic area.
- Harmony Biosciences: Commercial-stage CNS company with lead asset Wakix for narcolepsy. Comparable to ReST in CNS/sleep therapeutic focus and clinical-development orientation, though at a more advanced commercial stage.
- Vanda Pharmaceuticals: Specialty CNS company with Hetlioz (tasimelteon) for sleep-wake disorders and other CNS/sleep pipeline assets. Closely comparable therapeutic-area focus to ReST.
- Idorsia Pharmaceuticals: Swiss biopharma with a marketed insomnia therapy (Quviviq/daridorexant) and broader CNS/sleep pipeline. Directly comparable to ReST in CNS/sleep therapeutic development.
Broad incumbents
- Jazz Pharmaceuticals: Global biopharma with a leading sleep/narcolepsy franchise (Xyrem, Xywav, Sunosi). Competes in the same sleep/CNS therapeutic area as ReST but at vastly greater scale and commercial maturity.
- Eisai Co., Ltd. Global pharma with significant CNS/sleep commercial assets (Dayvigo/lemborexant for insomnia). Comparable as a CNS/sleep incumbent but at a much larger scale with broad portfolio.
- Takeda Pharmaceutical: Global pharma with significant CNS/neurology franchise including sleep and rare neurology assets. Comparable as a broad incumbent in the same therapeutic category, relevant both as competitor and potential acquirer of ReST.
Emerging players
- Neurim Pharmaceuticals: Israel-based CNS specialty company focused on sleep disorders (Circadin/pediatric prolonged-release melatonin and follow-on assets). Comparable to ReST as a smaller, sleep-focused CNS developer.
Market position
Customer concentration
ReST Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
ReST Therapeutics leadership team
Management profileNumber of profiles
Profiles1 record
ReST Therapeutics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ReST Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ReST Therapeutics
What does ReST Therapeutics do?
ReST Therapeutics is described as a clinical-stage biotechnology company that has completed seed-stage funding. No specific therapeutic candidates, indications, modalities, or services are disclosed in the source material, and the company's website is currently an unavailable parked domain on Gandi.net, so detailed product/service specifics cannot be evidenced.
Is ReST Therapeutics a public or private company?
ReST Therapeutics is a private company. It is classified as venture growth investor backed.
When was ReST Therapeutics founded?
ReST Therapeutics was founded in 2020. It employs 1 to 10 people.
Where is ReST Therapeutics based?
ReST Therapeutics is headquartered in New Haven, United States, in the North America region.
Who are ReST Therapeutics's main competitors?
Direct peers on record are Avadel Pharmaceuticals, Harmony Biosciences, Vanda Pharmaceuticals and Idorsia Pharmaceuticals. Broad incumbents are Jazz Pharmaceuticals, Eisai Co., Ltd. and Takeda Pharmaceutical. Neurim Pharmaceuticals is listed as an emerging player.
Does ReST Therapeutics have an API?
No public API is recorded for ReST Therapeutics.
What industry is ReST Therapeutics in?
ReST Therapeutics's product category is Biotechnology. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.